Table 1 Comparison between the excluded and the study samples characteristics (total N = 705)
Excluded sample (n = 113) | Study sample (n = 592) | Test comparing study sample with excluded sample characteristics | ||||
|---|---|---|---|---|---|---|
N | % or mean (sd) | N | % or mean (sd) | |||
Treatment (total N = 696) | Intensive chemotherapy | 7 | 7 | 187 | 32 | p* < 0.001 |
Best supporting care | 81 | 12 | 179 | 30 | ||
Hypomethylating agents | 12 | 3 | 175 | 7 | ||
Aracytine low dose | 3 | 78 | 42 | 30 | ||
Others | 1 | 1 | 9 | 1 | ||
Patient’s characteristics | ||||||
Age | Median (inter-quartile range) | 80 | 10 | 74 | 12 | p # < 0.001 |
Sex | Men | 59 | 52 | 364 | 61 | p § = 0.065 |
Women | 54 | 48 | 228 | 39 | ||
Patients’ SEP (EDI quintile) (total N = 613) | Q1 – least deprived | 3 | 14 | 124 | 21 | |
Q2 | 6 | 29 | 104 | 18 | ||
Q3 | 6 | 29 | 127 | 21 | p * = 0.388 | |
Q4 | 5 | 24 | 137 | 23 | ||
Q5 – most deprived | 1 | 5 | 100 | 17 | ||
Charlson comorbidity index | 0 | 20 | 19 | 261 | 44 | |
1 | 11 | 10 | 122 | 21 | p § = 0.001 | |
2+ | 12 | 11 | 104 | 18 | ||
Undefinable | 64 | 60 | 105 | 18 | ||
Performance status | 0/1 | 26 | 25 | 309 | 52 | |
2 | 13 | 13 | 91 | 15 | p § = 0.001 | |
3/4 | 10 | 10 | 60 | 10 | ||
Undefinable | 55 | 53 | 132 | 22 | ||
Tumor’s characteristics | ||||||
White blood cell counts (tercile) (total N = 599) | Tercile 1 – low | 1 | 14 | 195 | 33 | |
Tercile 2 – intermediate | 4 | 57 | 189 | 32 | p * = 0.393 | |
Tercile 3 – high | 2 | 29 | 193 | 33 | ||
Undefinable | 0 | 0 | 15 | 3 | ||
AML ontogeny (total N = 704) | AML de novo | 36 | 32 | 301 | 51 | |
Secondary AML (post treatment / MDS) | 41 | 37 | 268 | 45 | p § < 0.001 | |
Undefinable | 35 | 31 | 23 | 4 | ||
Cytogenetic initial prognosis | Favorable/Intermediate | 50 | 44 | 343 | 58 | p § < 0.001 |
Unfavorable | 26 | 23 | 203 | 34 | ||
Undefinable | 37 | 33 | 46 | 8 | ||